-transparent.png){kind=logo}
Induction of endotoxin tolerance or acute chlorpromazine treatment caused a decrease in bile and perfusate flow in the isolated perfused rat liver. The primary effects of each appeared to be on the bile acid-independent fraction of bile. Both the induction of endotoxin tolerance and the in vitro treatment of the perfused rat liver with endotoxin partially blocked the adverse effects of chlorpromazine on bile formation and perfusate flow. Although the "protective" effects of the in vitro endotoxin treatment were dose-dependent, the protection afforded by endotoxin tolerance was greater. Preincubation of isolated hepatocytes with endotoxin, before the addition of chlorpromazine, caused dose-dependent reductions in the chlorpromazine-induced release of aspartate transaminase. However, neither the incubation of endotoxin with chlorpromazine, before addition of membranes isolated from control rats, nor isolation of membranes from endotoxin-tolerant rats affected the inhibitory effects of chlorpromazine on sodium, potassium-, or magnesium-activated adenosine triphosphatase. If endotoxin exerts its protective effects at the membrane level, these data suggest that endotoxin is able to protect the intact, but not the isolated, hepatocyte membrane or that inhibition of adenosine triphosphatases by chlorpromazine is not important in the adverse effects of chlorpromazine on the perfused rat liver and isolated rat hepatocytes.
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
February 1978,
Virchows Archiv. B, Cell pathology,
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
July 1991,
Hepatology (Baltimore, Md.),
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
February 1981,
The Journal of clinical investigation,
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
May 1986,
The Journal of pharmacology and experimental therapeutics,
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
February 2009,
British journal of pharmacology,
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
February 1991,
Hepatology (Baltimore, Md.),
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
August 1990,
Hepatology (Baltimore, Md.),
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
July 1985,
The American journal of physiology,
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
January 1964,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
R Utili, and
C O Abernathy, and
H J Zimmerman, and
G B Gaeta, and
L Adinolfi, and
L Lukacs
July 1969,
Archives internationales de pharmacodynamie et de therapie,
